With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases

blonca9
Sep 5, 2024
1 min read

CEO Stéphane Boissel describes the company's first gene therapy program, with seeks to treat retinitis pigmentosa regardless of the mutational cause, and the future of its CRISPR/Cas9 gene editing partnership with Intellia.

Recent Posts

See All

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight